FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting

The FDA rejected a new cancer treatment from Summit Therapeutics and Akeso in a decision that analysts largely expected, but ultimately shouldn’t dim the prospects for a promising class of drugs. Regulators turned down ivonescimab ...